Want to see TSE:GUD full AI Analyst Report?
Total Valuation
Knight Therapeutics has a market cap or net worth of C$948.92M. The enterprise value is C$891.93.
Market CapC$948.92M
Enterprise ValueC$891.93
Share Statistics
Knight Therapeutics has 98,231,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,231,610
Owned by Insiders23.42%
Owned by Institutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.20%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.20%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee542.27K
Profits Per Employee-6.47K
Employee Count830
Asset Turnover0.43
Inventory Turnover2.20
Valuation Ratios
The current PE Ratio of Knight Therapeutics is 65.7. Knight Therapeutics’s PEG ratio is 0.50.
PE Ratio65.7
PS Ratio1.34
PB Ratio0.79
Price to Fair Value0.79
Price to FCF8.81
Price to Operating Cash Flow8.48
PEG Ratio0.50
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 450.09M and earned -5.37M in profits. Earnings per share was -0.05.
Revenue450.09M
Gross Profit150.74M
Operating Income-2.20M
Pretax Income-6.70M
Net Income-5.37M
EBITDA54.37M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was 112.90M and capital expenditures -4.86M, giving a free cash flow of 108.04M billion.
Operating Cash Flow112.90M
Free Cash Flow108.04M
Free Cash Flow per Share1.10
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change50.00%
50-Day Moving Average9.63
200-Day Moving Average7.48
Relative Strength Index (RSI)51.85
Average Volume (3m)48.52K
Important Dates
Knight Therapeutics upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 2.39, with Debt / Equity ratio of 4.29%
Current Ratio2.39
Quick Ratio1.57
Debt to Market Cap0.11
Net Debt to EBITDA0.03
Interest Coverage Ratio-0.21
Taxes
In the past 12 months, Knight Therapeutics has paid -1.33M in taxes.
Income Tax-1.33M
Effective Tax Rate0.20
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is 11.11, with an EV/FCF ratio of 8.83.
EV to Sales1.34
EV to EBITDA11.11
EV to Free Cash Flow8.83
EV to Operating Cash Flow8.59
Balance Sheet
Knight Therapeutics has C$109.60M in cash and marketable securities with C$34.28M in debt, giving a net cash position of C$75.32M billion.
Cash & Marketable SecuritiesC$109.60M
Total DebtC$34.28M
Net CashC$75.32M
Net Cash Per ShareC$0.77
Tangible Book Value Per ShareC$2.99
Margins
Gross margin is 36.88%, with operating margin of -0.49%, and net profit margin of -1.19%.
Gross Margin36.88%
Operating Margin-0.49%
Pretax Margin-1.49%
Net Profit Margin-1.19%
EBITDA Margin12.08%
EBIT Margin-0.49%
Analyst Forecast
The average price target for Knight Therapeutics is C$11.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$11.33
Price Target Upside16.48% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast42.32%
EPS Growth Forecast4332.35%